dc.contributor.author | Kelly, Vincent | en |
dc.contributor.author | Ghanim, Magda | en |
dc.contributor.author | Mc Manus, Gavin | en |
dc.contributor.author | Mok, Kenneth | en |
dc.date.accessioned | 2022-02-14T15:11:52Z | |
dc.date.available | 2022-02-14T15:11:52Z | |
dc.date.issued | 2021 | en |
dc.date.submitted | 2021 | en |
dc.identifier.citation | Ghanim M, Relitti N, McManus G, Butini S, Cappelli A, Campiani G, Mok KH, Kelly VP, A non-toxic, reversibly released imaging probe for oral cancer that is derived from natural compounds., Scientific reports, 2021 | en |
dc.identifier.other | Y | en |
dc.description | PUBLISHED | en |
dc.description.abstract | CD44 is emerging as an important receptor biomarker for various cancers. Amongst these is oral
cancer, where surgical resection remains an essential mode of treatment. Unfortunately, surgery is
frequently associated with permanent disfigurement, malnutrition, and functional comorbidities due
to the difficultly of tumour removal. Optical imaging agents that can guide tumour tissue identification
represent an attractive approach to minimising the impact of surgery. Here, we report the synthesis of
a water‑soluble fluorescent probe, namely HA‑FA‑HEG‑OE (compound 1), that comprises components
originating from natural sources: oleic acid, ferulic acid and hyaluronic acid. Compound 1 was found
to be non‑toxic, displayed aggregation induced emission and accumulated intracellularly in vesicles in
SCC‑9 oral squamous cells. The uptake of 1 was fully reversible over time. Internalization of compound
1 occurs through receptor mediated endocytosis; uniquely mediated through the CD44 receptor.
Uptake is related to tumorigenic potential, with non‑tumorigenic, dysplastic DOK cells and poorly
tumorigenic MCF‑7 cells showing only low intracellular levels and highlighting the critical role of
endocytosis in cancer progression and metastasis. Together, the recognised importance of CD44 as a
cancer stem cell marker in oral cancer, and the reversible, non‑toxic nature of 1, makes it a promising
agent for real time intraoperative imaging. | en |
dc.language.iso | en | en |
dc.relation.ispartofseries | Scientific reports | en |
dc.rights | Y | en |
dc.subject | CD44 | en |
dc.subject | cancers | en |
dc.subject | HA‑FA‑HEG‑OE (compound 1) | en |
dc.subject.lcsh | CD44 | en |
dc.subject.lcsh | cancers | en |
dc.subject.lcsh | HA‑FA‑HEG‑OE (compound 1) | en |
dc.title | A non-toxic, reversibly released imaging probe for oral cancer that is derived from natural compounds. | en |
dc.type | Journal Article | en |
dc.type.supercollection | scholarly_publications | en |
dc.type.supercollection | refereed_publications | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/kellyvp | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/mok1 | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/mghanim | en |
dc.identifier.peoplefinderurl | http://people.tcd.ie/mcmanug | en |
dc.identifier.rssinternalid | 232214 | en |
dc.identifier.doi | https://doi.org/10.1038/s41598-021-93408-0 | en |
dc.relation.ecprojectid | info:eu-repo/grantAgreement/EC/FP7/721906-TRACT | |
dc.rights.ecaccessrights | openAccess | |
dc.subject.TCDTheme | Cancer | en |
dc.subject.TCDTag | CANCER | en |
dc.subject.TCDTag | CANCER CELLS | en |
dc.subject.TCDTag | Cancer Detection | en |
dc.subject.TCDTag | Cancer Screening | en |
dc.identifier.orcid_id | 0000-0001-7067-5407 | en |
dc.subject.darat_thematic | Health | en |
dc.status.accessible | N | en |
dc.contributor.sponsor | Other | en |
dc.contributor.sponsorGrantNumber | POR-FSE 2014-2020 | en |
dc.contributor.sponsor | European Union (EU) | en |
dc.contributor.sponsorGrantNumber | 721906-TRACT | en |
dc.identifier.uri | http://hdl.handle.net/2262/98094 | |